Enhanced sensitivity to different BH3-mimetics after CHOP treatment was confirmed in specific cell lines, indicating heterogeneity of CHOP-induced resistance in DLBCL. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.